{"id":"cholic-acids","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cholic acid functions as a replacement therapy for patients with deficient endogenous bile acid synthesis, particularly in cerebrotendinous xanthomatosis (CTX) and other inborn errors of bile acid metabolism. By supplementing the deficient primary bile acid pool, it restores normal enterohepatic circulation, improves fat-soluble vitamin absorption, and reduces accumulation of toxic bile acid precursors. This mechanism addresses the underlying metabolic defect rather than treating symptoms alone.","oneSentence":"Cholic acid is a primary bile acid that restores bile acid-dependent signaling pathways to improve cholestasis and fat malabsorption in patients with bile acid synthesis disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:46.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cerebrotendinous xanthomatosis (CTX)"},{"name":"Progressive familial intrahepatic cholestasis (PFIC)"},{"name":"Bile acid synthesis disorders"}]},"trialDetails":[{"nctId":"NCT06783621","phase":"PHASE4","title":"A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-01-16","conditions":"Facial Contouring","enrollment":130},{"nctId":"NCT06517862","phase":"PHASE4","title":"Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia","status":"RECRUITING","sponsor":"Amira Adel Fouly","startDate":"2024-09-01","conditions":"Neonatal Hyperbilirubinemia","enrollment":80},{"nctId":"NCT03724175","phase":"PHASE2, PHASE3","title":"The Role of Secondary Bile Acids in Intestinal Inflammation","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-08-26","conditions":"Ulcerative Colitis, Pouchitis","enrollment":2},{"nctId":"NCT01907074","phase":"PHASE2","title":"Quantitative Liver Function Tests Using Cholates","status":"TERMINATED","sponsor":"Baylor Research Institute","startDate":"2011-06-23","conditions":"End Stage Liver Disease","enrollment":103},{"nctId":"NCT07378761","phase":"PHASE2","title":"Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-02","conditions":"Immune-Mediated Cholestasis","enrollment":94},{"nctId":"NCT05751967","phase":"PHASE3","title":"Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-02-22","conditions":"Primary Biliary Cholangitis","enrollment":150},{"nctId":"NCT06755541","phase":"PHASE3","title":"Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-01-30","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":150},{"nctId":"NCT00200343","phase":"PHASE3","title":"Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2002-07","conditions":"Chronic Hepatitis C","enrollment":596},{"nctId":"NCT07296458","phase":"PHASE3","title":"FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2025-12-15","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":132},{"nctId":"NCT06091787","phase":"NA","title":"Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-09-01","conditions":"Liver Regeneration, Ursodeoxycholic Acid, Partial Liver Resection","enrollment":90},{"nctId":"NCT06922669","phase":"NA","title":"Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Drug Induced Liver Injury","enrollment":232},{"nctId":"NCT07273734","phase":"NA","title":"UDCA to Prevent Post-TIPS Hepatic Encephalopathy","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-01","conditions":"Hepatic Encephalopathy (HE), TIPS","enrollment":270},{"nctId":"NCT07110987","phase":"NA","title":"The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect Hyperbilirubinemia","status":"RECRUITING","sponsor":"Tishreen University Hospital","startDate":"2025-06-26","conditions":"Hyperbilirubinemia, Neonatal Indirect","enrollment":70},{"nctId":"NCT06610760","phase":"PHASE4","title":"Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2024-11-12","conditions":"Gastric Intestinal Metaplasia","enrollment":196},{"nctId":"NCT07237425","phase":"PHASE1","title":"Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma","status":"RECRUITING","sponsor":"Glonova Pharma Co., Ltd","startDate":"2025-11-14","conditions":"Lipoma, Submental Fullness","enrollment":56},{"nctId":"NCT06591468","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics","status":"ENROLLING_BY_INVITATION","sponsor":"Han Ying","startDate":"2024-10-30","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":244},{"nctId":"NCT06591455","phase":"EARLY_PHASE1","title":"A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Han Ying","startDate":"2024-09-14","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":30},{"nctId":"NCT06132165","phase":"PHASE1","title":"Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2024-03-01","conditions":"Neurofibromatosis 1","enrollment":13},{"nctId":"NCT06300502","phase":"PHASE1","title":"Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)","status":"ENROLLING_BY_INVITATION","sponsor":"Massachusetts General Hospital","startDate":"2025-04-08","conditions":"Neurofibromas, Cutaneous, Neurofibromatosis 1","enrollment":15},{"nctId":"NCT06884748","phase":"EARLY_PHASE1","title":"Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-12-01","conditions":"Clostridioides Difficile Infection","enrollment":30},{"nctId":"NCT06684106","phase":"NA","title":"Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-11-25","conditions":"Hyperlipidemia, Ursodeoxycholic Acid, Statin Therapy","enrollment":128},{"nctId":"NCT02314208","phase":"PHASE2","title":"Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2015-01-08","conditions":"Spastic Paraplegia, Hereditary","enrollment":12},{"nctId":"NCT07102979","phase":"NA","title":"Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response","status":"ENROLLING_BY_INVITATION","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-09-01","conditions":"Liver Cirrhosis","enrollment":150},{"nctId":"NCT00457639","phase":"PHASE2","title":"Cholic Acid for Hepatic Steatosis in Lipodystrophy","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2006-04","conditions":"Hepatic Steatosis","enrollment":18},{"nctId":"NCT07068191","phase":"NA","title":"Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly","status":"RECRUITING","sponsor":"Phenomen Pharma","startDate":"2025-06-19","conditions":"Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL)","enrollment":90},{"nctId":"NCT07072949","phase":"PHASE1","title":"The Impact of Ursodeoxycholic Acid and Probiotics on Metabolic Outcomes in Type 2 Diabetic Patients Taking Metformin","status":"COMPLETED","sponsor":"University of Banja Luka","startDate":"2023-01-03","conditions":"Type 2 Diabetes Mellitus","enrollment":90},{"nctId":"NCT00873275","phase":"PHASE1","title":"Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2009-03-11","conditions":"Colorectal Cancer","enrollment":11},{"nctId":"NCT06294847","phase":"PHASE3","title":"Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2024-08-20","conditions":"Retinal Detachment","enrollment":120},{"nctId":"NCT03284034","phase":"NA","title":"Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-11-27","conditions":"Upper Back Fat","enrollment":8},{"nctId":"NCT04407650","phase":"PHASE4","title":"Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College London","startDate":"2021-07-01","conditions":"Gestational Diabetes","enrollment":64},{"nctId":"NCT06918080","phase":"PHASE4","title":"Hepatoprotective Measures for Children at High Risk of NAFLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2023-11-19","conditions":"Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia","enrollment":200},{"nctId":"NCT04650243","phase":"PHASE4","title":"Clinical Research of Tapering UDCA in PBC Patients With a Complete Response","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2020-01-21","conditions":"Primary Biliary Cholangitis","enrollment":90},{"nctId":"NCT03188146","phase":"","title":"Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2017-05-01","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":57},{"nctId":"NCT04924868","phase":"PHASE3","title":"Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis","status":"RECRUITING","sponsor":"Hospital General Universitario de Alicante","startDate":"2021-11-10","conditions":"Acute Pancreatitis Due to Gallstones","enrollment":332},{"nctId":"NCT06842472","phase":"PHASE2","title":"PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT05659654","phase":"PHASE1, PHASE2","title":"The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-16","conditions":"COVID-19","enrollment":95},{"nctId":"NCT04730583","phase":"PHASE1","title":"Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-06-02","conditions":"Cutaneous Neurofibroma","enrollment":34},{"nctId":"NCT06120036","phase":"PHASE1","title":"Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2022-12-06","conditions":"Neurofibromatosis 1","enrollment":20},{"nctId":"NCT06639425","phase":"NA","title":"Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes","status":"RECRUITING","sponsor":"Beijing Chao Yang Hospital","startDate":"2024-10-12","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06260748","phase":"PHASE3","title":"A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)","status":"WITHDRAWN","sponsor":"Leadiant Biosciences, Inc.","startDate":"2024-05-27","conditions":"Cerebrotendinous Xanthomatoses","enrollment":""},{"nctId":"NCT05925309","phase":"NA","title":"Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-07-01","conditions":"Biliary Atresia, Cholangitis, Anti-Bacterial Agents","enrollment":356},{"nctId":"NCT06629909","phase":"PHASE1","title":"Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Baermed","startDate":"2024-12-01","conditions":"Liver Cirrhosis","enrollment":54},{"nctId":"NCT00909610","phase":"PHASE1","title":"Ursodiol Tablets 500 mg Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-12","conditions":"Healthy","enrollment":80},{"nctId":"NCT00909753","phase":"PHASE1","title":"Ursodiol 500 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-09","conditions":"Healthy","enrollment":92},{"nctId":"NCT04640571","phase":"PHASE4","title":"Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-04-01","conditions":"Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80","enrollment":18},{"nctId":"NCT03004118","phase":"PHASE4","title":"Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2017-01","conditions":"Functional Dyspepsia","enrollment":16},{"nctId":"NCT06278090","phase":"","title":"Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution","status":"RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2024-03-01","conditions":"Gallbladder Polyp","enrollment":36},{"nctId":"NCT05973370","phase":"PHASE2","title":"Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-05-01","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT03720990","phase":"PHASE1, PHASE2","title":"Smith-Lemli-Opitz Syndrome and Cholic Acid","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2021-03-27","conditions":"Smith-Lemli-Opitz Syndrome","enrollment":12},{"nctId":"NCT05526807","phase":"NA","title":"Ursodeoxycholic Acid in C. Difficile Infection","status":"TERMINATED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2019-05-08","conditions":"Clostridioides Difficile Infection","enrollment":6},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT00550862","phase":"PHASE2","title":"Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2007-10","conditions":"Liver Cirrhosis, Biliary","enrollment":165},{"nctId":"NCT06180057","phase":"PHASE1","title":"Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2022-06-12","conditions":"Cerebrotendinous Xanthomatoses","enrollment":24},{"nctId":"NCT06127355","phase":"PHASE3","title":"Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' Gestation","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2021-03-03","conditions":"Gestational Diabetes","enrollment":113},{"nctId":"NCT01115582","phase":"PHASE3","title":"Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2010-04","conditions":"Inborn Errors of Bile Acid Synthesis","enrollment":16},{"nctId":"NCT01438411","phase":"PHASE3","title":"Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2010-01","conditions":"Bile Acid Synthesis Defect","enrollment":53},{"nctId":"NCT00007020","phase":"PHASE3","title":"Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"1992-01","conditions":"Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy","enrollment":85},{"nctId":"NCT03115086","phase":"","title":"The REPLACE Registry for Cholbam® (Cholic Acid)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2017-07-10","conditions":"Bile Acid Synthesis Disorders","enrollment":55},{"nctId":"NCT05902468","phase":"PHASE2, PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":"Diabetes Mellitus, Type 2","enrollment":88},{"nctId":"NCT03602976","phase":"PHASE2","title":"Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis","status":"TERMINATED","sponsor":"Ethan Weinberg","startDate":"2018-08-20","conditions":"Hepatic Sarcoidosis, Elevated Alkaline Phosphatase","enrollment":7},{"nctId":"NCT04076527","phase":"","title":"Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis","status":"UNKNOWN","sponsor":"University of Leipzig","startDate":"2019-09-19","conditions":"PBC, Primary Biliary Cholangitis","enrollment":1200},{"nctId":"NCT05874336","phase":"PHASE1","title":"An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol","status":"COMPLETED","sponsor":"Galmed Pharmaceuticals Ltd","startDate":"2020-06-17","conditions":"NASH","enrollment":6},{"nctId":"NCT05416580","phase":"PHASE3","title":"Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"University of Banja Luka","startDate":"2022-09-12","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT05849558","phase":"PHASE4","title":"Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2022-02-22","conditions":"Chronic Liver Disease","enrollment":297},{"nctId":"NCT05832697","phase":"PHASE1","title":"An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-01-27","conditions":"Healthy Subject","enrollment":44},{"nctId":"NCT05812612","phase":"","title":"UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2023-01-30","conditions":"COVID-19 Infection","enrollment":2000},{"nctId":"NCT05690646","phase":"PHASE4","title":"Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-01-28","conditions":"Cardiac Surgery","enrollment":491},{"nctId":"NCT04834557","phase":"PHASE2","title":"Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-11-01","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT04542473","phase":"PHASE2, PHASE3","title":"Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-07-01","conditions":"SEPSIS, MALNUTRITION, CHILD","enrollment":400},{"nctId":"NCT04531878","phase":"PHASE2, PHASE3","title":"BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2023-02-08","conditions":"Hereditary Diseases, Cholestasis, Intrahepatic","enrollment":""},{"nctId":"NCT05467553","phase":"PHASE2","title":"A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-02-24","conditions":"Hepatitis D","enrollment":30},{"nctId":"NCT04910178","phase":"PHASE4","title":"Follow-up of NAFLD Patients With MRI-PDFF","status":"COMPLETED","sponsor":"Asmaa Abdelfattah Elsayed","startDate":"2020-12-01","conditions":"Diabetes Type 2, NAFLD","enrollment":80},{"nctId":"NCT04810156","phase":"PHASE2","title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","status":"UNKNOWN","sponsor":"Inge Marie Svane","startDate":"2021-04-07","conditions":"Hepatitis, Drug-Induced","enrollment":60},{"nctId":"NCT05500937","phase":"PHASE2, PHASE3","title":"Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-03-01","conditions":"Diabetes Mellitus","enrollment":1000},{"nctId":"NCT05499026","phase":"","title":"Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)","status":"COMPLETED","sponsor":"Leadiant Biosciences Ltd.","startDate":"2014-12-09","conditions":"Cerebrotendinous Xanthomatoses","enrollment":28},{"nctId":"NCT01589523","phase":"PHASE3","title":"GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2006-02","conditions":"Bile Acid Synthesis Defect, Inborn Error of Bile Acid Metabolism, Inborn Error of Bile Acid Conjugation","enrollment":5},{"nctId":"NCT03168555","phase":"PHASE4","title":"Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2017-06-22","conditions":"Bile Acid Malabsorption, Cholelithiasis","enrollment":23},{"nctId":"NCT02967250","phase":"PHASE1","title":"Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-04-01","conditions":"Parkinson Disease","enrollment":5},{"nctId":"NCT03844100","phase":"PHASE1, PHASE2","title":"Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2019-11-01","conditions":"Dyspepsia, Biliary Dysplasia","enrollment":37},{"nctId":"NCT02748616","phase":"PHASE4","title":"C. Difficile and Ursodiol","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-03-01","conditions":"Diarrhea","enrollment":9},{"nctId":"NCT03510598","phase":"PHASE4","title":"Submental Study (Sequential Treatment Approach)","status":"COMPLETED","sponsor":"Zeltiq Aesthetics","startDate":"2018-03-27","conditions":"Body Fat Disorder","enrollment":16},{"nctId":"NCT02936596","phase":"NA","title":"Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome","status":"UNKNOWN","sponsor":"Xiaoli Fan","startDate":"2016-12","conditions":"Hepatitis, Autoimmune, Cholangitis, Liver Cirrhosis, Biliary","enrollment":53},{"nctId":"NCT02021110","phase":"PHASE2","title":"Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-12","conditions":"Polycystic Liver Disease, Polycystic Kidney, Autosomal Dominant","enrollment":34},{"nctId":"NCT05043194","phase":"NA","title":"Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis","status":"UNKNOWN","sponsor":"Wei Liu","startDate":"2021-01-01","conditions":"Cholestasis of Parenteral Nutrition","enrollment":80},{"nctId":"NCT02965911","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA","status":"WITHDRAWN","sponsor":"Beijing 302 Hospital","startDate":"2016-01","conditions":"Primary Biliary Cirrhosis","enrollment":""},{"nctId":"NCT04281082","phase":"","title":"Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives","status":"UNKNOWN","sponsor":"Alexandra Hospital, Athens, Greece","startDate":"2018-01-01","conditions":"Cholestasis of Pregnancy","enrollment":50},{"nctId":"NCT04977661","phase":"PHASE4","title":"Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2020-02-01","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":102},{"nctId":"NCT00059202","phase":"PHASE2, PHASE3","title":"Trial of High-dose Urso in Primary Sclerosing Cholangitis","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2002-07","conditions":"Primary Sclerosing Cholangitis","enrollment":150},{"nctId":"NCT03201952","phase":"PHASE1","title":"Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-02-01","conditions":"Glucose Intolerance, Gastric Bypass Surgery","enrollment":2},{"nctId":"NCT04089722","phase":"PHASE4","title":"Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the \"Bra Strap Fat\" Region","status":"COMPLETED","sponsor":"Juva Skin & Laser Center","startDate":"2019-07-26","conditions":"Brassiere Strap Fat (BSF), Bra Strap Fat (BSF)","enrollment":22},{"nctId":"NCT04617561","phase":"PHASE4","title":"Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-11-01","conditions":"Hepatitis, Autoimmune, Primary Biliary Cholangitis","enrollment":90},{"nctId":"NCT04786795","phase":"PHASE4","title":"MITE in the Treatment of Dyspepsia After Cholecystectomy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2021-03-01","conditions":"Patients With Dyspeptic Symptoms After Cholecystectomy","enrollment":990},{"nctId":"NCT03678480","phase":"PHASE2","title":"A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)","status":"WITHDRAWN","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2021-03-01","conditions":"Primary Sclerosing Cholangitis, Cholangitis, Cholangitis, Sclerosing","enrollment":""},{"nctId":"NCT04751188","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis","status":"UNKNOWN","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2020-10-02","conditions":"Primary Biliary Cirrhosis","enrollment":11},{"nctId":"NCT03664596","phase":"NA","title":"Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan","startDate":"2018-08-01","conditions":"Non-alcoholic Steatohepatitis","enrollment":80},{"nctId":"NCT03665519","phase":"NA","title":"Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"National Scientific Medical Center, Kazakhstan","startDate":"2018-01-03","conditions":"Primary Biliary Cirrhosis","enrollment":40},{"nctId":"NCT04054011","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2019-07-05","conditions":"Adiposity","enrollment":15},{"nctId":"NCT03691415","phase":"","title":"Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea","status":"TERMINATED","sponsor":"Allergan","startDate":"2018-09-07","conditions":"Submental Fullness","enrollment":71},{"nctId":"NCT02876484","phase":"PHASE4","title":"Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2016-06","conditions":"Severe Obesity","enrollment":12},{"nctId":"NCT02952963","phase":"PHASE4","title":"Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2016-10","conditions":"Severe Obesity","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":159,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cholic","Cholic Acid","Cholic Acid Capsules"],"phase":"phase_3","status":"active","brandName":"Cholic Acids","genericName":"Cholic Acids","companyName":"Mirum Pharmaceuticals, Inc.","companyId":"mirum-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cholic acid is a primary bile acid that restores bile acid-dependent signaling pathways to improve cholestasis and fat malabsorption in patients with bile acid synthesis disorders. Used for Cerebrotendinous xanthomatosis (CTX), Progressive familial intrahepatic cholestasis (PFIC), Bile acid synthesis disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}